Etoposide is a topoisomerase inhibitor indicated in the management of small Cell Lung Cancer —Etoposide capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. MedsAcross supplies Etoposide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer —Etoposide capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.
Source: US FDA prescribing information
For recommended dosing adjustments in patients with renal impairment see PRECAUTIONS section. Chemotherapy courses are repeated at 3 to 4-week intervals after adequate recovery from any toxicity. VePesid Capsules In small cell lung cancer, the recommended dose of etoposide capsules is two times the IV dose rounded to the nearest 50 mg (i.e., two times 35 mg/m 2 /day for 4 days to 50 mg/m 2 /day for 5 days). The dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve. Administration Precautions To minimize the risk of dermal exposure, always wear impervious gloves when handling blister packs of individually labeled blisters containing VePesid capsules.
Source: US FDA prescribing information
VePesid is contraindicated in patients who have demonstrated a previous hypersensitivity to etoposide or any component of the formulation.
Source: US FDA prescribing information
VePesid (etoposide) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur. Patients being treated with VePesid must be frequently observed for myelosuppression both during and after therapy. Myelosuppression resulting in death has been reported. Dose-limiting bone marrow suppression is the most significant toxicity associated with VePesid therapy. Therefore, the following studies should be obtained at the start of therapy and prior to each subsequent cycle of VePesid: platelet count, hemoglobin, white blood cell count, and differential. The occurrence of a platelet count below 50,000/mm 3 or an absolute neutrophil count below 500/mm 3 is an indication to withhold further therapy until the blood counts have sufficiently recovered.
Source: US FDA prescribing information
The following data on adverse reactions are based on both oral and intravenous administration of VePesid as a single agent, using several different dose schedules for treatment of a wide variety of malignancies. Hematologic Toxicity Myelosuppression is dose related and dose limiting, with granulocyte nadirs occurring 7 to 14 days after drug administration and platelet nadirs occurring 9 to 16 days after drug administration. Bone marrow recovery is usually complete by day 20, and no cumulative toxicity has been reported. Fever and infection have also been reported in patients with neutropenia. Death associated with myelosuppression has been reported. The occurrence of acute leukemia with or without a preleukemic phase has been reported rarely in patients treated with VePesid in association with other antineoplastic agents.
Source: US FDA prescribing information
Capsules are to be stored under refrigeration, between 2°C to 8°C (36°F to 46°F). DO NOT FREEZE.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Etoposide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Etoposide 100 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Etoposide 1000 mg/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Etoposide 500 mg/25 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| VePesid 50 mg capsuleOral Cold chain | Onesource Specialty Pharma | US FDA | Available on request |
| Avopef 100 mg/5 mL injectionIntravenous | Avyxa Pharma | US FDA | Available on request |
| Avopef 500 mg/25 mL injectionIntravenous | Avyxa Pharma | US FDA | Available on request |
| Etopophos 100 mg powder for injectionIntravenous Cold chain | H2-Pharma | US FDA | Available on request |
| Etoposide 50 mg capsuleOral Cold chainGeneric name | — | US FDA | Available on request |
3 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 10 November 1983 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Etoposide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Etoposide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Etoposide, including Avopef, Etopophos, VePesid.
Yes. The US FDA first approved Etoposide on 10 November 1983, according to Drugs@FDA.
At least one listed presentation of Etoposide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Etoposide is classified under ATC code L01CB01 (Etoposide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.